Improving Trend in FDA First Cycle Review Approvals a Major Factor for Biotech Industry's Success in 2012

 The Biotech Industry has skyrocketed in 2012 as an increase in the number of new drug approvals has boosted investor optimism within the industry. The iShares Nasdaq Biotechnology Index Fund (IBB) and the SPDR S&P Biotech ETF (XBI) have both gained over 25 percent year-to-date.

Read More:

www.marketwire.com/press-release/improving-trend-fda-first-cycle-review-approvals-major-factor-biotech-industrys-success-nasdaq-chtp-1727420.htm